Emerging evidence suggests GLP-1s may hold promise as an added therapeutic option, but further clinical trials in humans are necessary to determine the safety, efficacy, and role in addiction treatment
Nevertheless, some pharmacological evidence suggests discontinuing the use of Semaglutide once pregnancy is confirmed to steer away from any possibility of fetal suffering
6.4 Doses and comparators in the global trials (PIONEER 18) In the PIONEER studies, oral semaglutide doses of 14 mg, 7 mg, and in some cases, 3 mg, were tested against either placebo or active comparators [38, 39, 61, 62, 76,77,78,79,80,81,82,83,84]
Neck pain presents itself in different forms depending on the individual and the underlying cause
& Barrera-Saldaa, H
WHO issues global guideline on the use of GLP-1 medicines in treating obesity